The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Insurers Often Limit Biosimilar Coverage

U.S. Insurers Often Limit Biosimilar Coverage

May 29, 2020 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—U.S. commercial health plans only covered biosimilar treatments as preferred products in 14% of coverage decisions last year, according to an analysis of publicly available data on coverage decisions.1

You Might Also Like
  • Health Plans Enact Coverage Policies for Remicade & Infliximab Biosimilars
  • Commercial Insurers Extend Coverage for Telehealth Services
  • Medicare Drug Coverage Plans for Rheumatologic Medications

Researchers examined records from the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database, which has information on coverage decisions made by 17 of the largest U.S. health plans that publicly share this data.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Based on 535 coverage decisions in 2019 that involved 9 biosimilars and 40 drug-indication pairings of biosimilars and reference products for the same indication, biosimilars received non-preferred status in 33% of cases and on par status in 53% of decisions.

“These findings have important implications for patients, as they mean that a patient’s insurer can affect their access to biosimilars,” says lead study author James Chambers of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, Boston.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Our findings may also have important implications for patients transitioning between insurers, as differences in insurance plans’ coverage decisions may result in care disruptions,” Mr. Chambers says by email.

The health plans in the study issued a median of 32 biosimilar coverage decisions, with a range of 18 to 40 decisions.

Researchers looked at nine biosimilar drugs: bevacizumab-awwb, epoetin alpha-epbx, filgrastim-aafi, filgrastim-sndz, infliximab-abda, infliximab-dyyb, pegfilgrastim-cbqv, pegfilgrastim-jmdb and trastuzumab-anns.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Across all of the health plans in the study, the media number of coverage decisions for an individual biosimilar was 56, and ranged from 12 to 134.

Seven health plans covered a biosimilar as preferred in at least one decision, and only two of these plans preferred biosimilars in at least half of their coverage decisions.

Decisions also varied by drug. Although 51% of plans covered filgrastim-sndz as preferred, for example, 65% of plans covered infliximab-abda as non-preferred.

Researchers lacked data to explain why there was so much variation in coverage decisions, and they also lacked information on any negotiated rebates that may have contributed to any decisions based on the relative costs of different drugs.

Drug characteristics, such as the time since U.S. Food and Drug Administration (FDA) approval or whether the drug treats cancer, may explain some of the variation, the authors note.

“Insurance plans and their Pharmacy Benefit Managers (PBMs) seek deals with drug manufacturers not only based on discounts from the list price, but by negotiating rebates,” says Donald Miller, a professor of pharmacy practice at North Dakota State University, Fargo, who wasn’t involved in the study.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biosimilars, Health Insurance, infliximab-abda, infliximab-dyyb, pharmacy benefit managers (PBMs)

You Might Also Like:
  • Health Plans Enact Coverage Policies for Remicade & Infliximab Biosimilars
  • Commercial Insurers Extend Coverage for Telehealth Services
  • Medicare Drug Coverage Plans for Rheumatologic Medications
  • Biosimilar Prescribing Habits in the VA & Academic Settings

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.